• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Premature Ovarian Failure - Pipeline Review, H2 2012 Product Image

Premature Ovarian Failure - Pipeline Review, H2 2012

  • Published: November 2012
  • 33 pages
  • Global Markets Direct

Premature Ovarian Failure – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Premature Ovarian Failure - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Premature Ovarian Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ovarian Failure. Premature Ovarian Failure - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Premature Ovarian Failure.
- A review of the Premature Ovarian Failure products under READ MORE >

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Premature Ovarian Failure Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Premature Ovarian Failure 7
Premature Ovarian Failure Therapeutics under Development by Companies 9
Premature Ovarian Failure Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Premature Ovarian Failure Therapeutics – Products under Development by Companies 16
Premature Ovarian Failure Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Premature Ovarian Failure Therapeutics Development 18
Respiratorius AB 18
Premature Ovarian Failure – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
SPOC - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Cyclophosphamide + Goserelin - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
estradiol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Triptorelin + Norethisterone Acetate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
prasterone - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PTEN Inhibitor - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Premature Ovarian Failure, H2 2012 7
Products under Development for Premature Ovarian Failure – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Respiratorius AB, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24

List of Figures
Number of Products under Development for Premature Ovarian Failure, H2 2012 7
Products under Development for Premature Ovarian Failure – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos